The Lancet has recently published an update to the progression-free survival (PFS) data of theICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.)
ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial. ICON6 is designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib (AZD2171) in women with platinum-sensitive relapsed ovarian cancer. In the trial, cediranib was administered during platinum-based chemotherapy only (concurrent cediranib), or given during chemotherapy and continued as single agent maintenance therapy (concurrent and maintenance cediranib).
The results, published this month, show that there is a benefit to be derived from the use of cediranib (AZD171) when given concurrently with chemotherapy and continued as maintenance for patients with platinum sensitive ovarian cancer when compared to standard chemotherapy only, albiet with some significant toxicities.
The secondary endpoint of overall survival will require more follow up before analysis.
